TY - JOUR
T1 - Drugs repurposed as antiferroptosis agents suppress organ damage, including aki, by functioning as lipid peroxyl radical scavengers
AU - Mishima, Eikan
AU - Sato, Emiko
AU - Ito, Junya
AU - Yamada, Ken Ichi
AU - Suzuki, Chitose
AU - Oikawa, Yoshitsugu
AU - Matsuhashi, Tetsuro
AU - Kikuchi, Koichi
AU - Toyohara, Takafumi
AU - Suzuki, Takehiro
AU - Ito, Sadayoshi
AU - Nakagawa, Kiyotaka
AU - Abe, Takaaki
N1 - Funding Information:
We acknowledge the support of the Biomedical Research Core of Tohoku University Graduate School of Medicine. We are grateful to Prof. Jeffrey B. Kopp for providing human urine-derived podocyte-like epithelial cells, and thank Y. Sasaki for technical assistance and Keyence Corporation for the use of a BZX-810 microscope.
Publisher Copyright:
© 2020 by the American Society of Nephrology.
PY - 2020
Y1 - 2020
N2 - Background Ferroptosis, nonapoptotic cell death mediated by free radical reactions and driven by the oxidative degradation of lipids, is a therapeutic target because of its role in organ damage, including AKI. Ferroptosis-causing radicals that are targeted by ferroptosis suppressors have not been unequivocally identified. Because certain cytochrome P450 substrate drugs can prevent lipid peroxidation via obscure mechanisms, we evaluated their antiferroptotic potential and used them to identify ferroptosis-causing radicals. Methods Using a cell-based assay, we screened cytochrome P450 substrate compounds to identify drugs with antiferroptotic activity and investigated the underlying mechanism. To evaluate radical-scavenging activity, we used electron paramagnetic resonance-spin trapping methods and a fluorescence probe for lipid radicals, NBD-Pen, that we had developed.We then assessed the therapeutic potency of these drugs in mouse models of cisplatin-induced AKI and LPS/galactosamine-induced liver injury. Results We identified various US Food and Drug Administration-approved drugs and hormones that have antiferroptotic properties, including rifampicin, promethazine, omeprazole, indole-3-carbinol, carvedilol, propranolol, estradiol, and thyroid hormones. The antiferroptotic drug effects were closely associated with the scavenging of lipid peroxyl radicals but not significantly related to interactions with other radicals. The elevated lipid peroxyl radical levels were associated with ferroptosis onset, and known ferroptosis suppressors, such as ferrostatin-1, also functioned as lipid peroxyl radical scavengers. The drugs exerted antiferroptotic activities in various cell types, includingtubules, podocytes, and renal fibroblasts.Moreover, inmice, thedrugs ameliorated AKI and liver injury, with suppression of tissue lipid peroxidation and decreased cell death. Conclusions Although elevated lipid peroxyl radical levels can trigger ferroptosis onset, some drugs that scavenge lipid peroxyl radicals can help control ferroptosis-related disorders, including AKI.
AB - Background Ferroptosis, nonapoptotic cell death mediated by free radical reactions and driven by the oxidative degradation of lipids, is a therapeutic target because of its role in organ damage, including AKI. Ferroptosis-causing radicals that are targeted by ferroptosis suppressors have not been unequivocally identified. Because certain cytochrome P450 substrate drugs can prevent lipid peroxidation via obscure mechanisms, we evaluated their antiferroptotic potential and used them to identify ferroptosis-causing radicals. Methods Using a cell-based assay, we screened cytochrome P450 substrate compounds to identify drugs with antiferroptotic activity and investigated the underlying mechanism. To evaluate radical-scavenging activity, we used electron paramagnetic resonance-spin trapping methods and a fluorescence probe for lipid radicals, NBD-Pen, that we had developed.We then assessed the therapeutic potency of these drugs in mouse models of cisplatin-induced AKI and LPS/galactosamine-induced liver injury. Results We identified various US Food and Drug Administration-approved drugs and hormones that have antiferroptotic properties, including rifampicin, promethazine, omeprazole, indole-3-carbinol, carvedilol, propranolol, estradiol, and thyroid hormones. The antiferroptotic drug effects were closely associated with the scavenging of lipid peroxyl radicals but not significantly related to interactions with other radicals. The elevated lipid peroxyl radical levels were associated with ferroptosis onset, and known ferroptosis suppressors, such as ferrostatin-1, also functioned as lipid peroxyl radical scavengers. The drugs exerted antiferroptotic activities in various cell types, includingtubules, podocytes, and renal fibroblasts.Moreover, inmice, thedrugs ameliorated AKI and liver injury, with suppression of tissue lipid peroxidation and decreased cell death. Conclusions Although elevated lipid peroxyl radical levels can trigger ferroptosis onset, some drugs that scavenge lipid peroxyl radicals can help control ferroptosis-related disorders, including AKI.
UR - http://www.scopus.com/inward/record.url?scp=85078868692&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078868692&partnerID=8YFLogxK
U2 - 10.1681/ASN.2019060570
DO - 10.1681/ASN.2019060570
M3 - Article
C2 - 31767624
AN - SCOPUS:85078868692
SN - 1046-6673
VL - 31
SP - 280
EP - 296
JO - Journal of the American Society of Nephrology : JASN
JF - Journal of the American Society of Nephrology : JASN
IS - 2
ER -